You are here

FDA Approval for CIP-Fenofibrate

MISSISSAUGA, ON, Jan. 13 /PRNewswire-FirstCall/ -- Cipher Pharmaceuticals Inc. (TSX: DND) today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for CIP-Fenofibrate, the Company's novel formulation of the active ingredient fenofibrate, which is used in the treatment of hyperlipidemia. CIP-Fenofibrate, approved under the label as Lipofen(TM), targets a large and growing market as the three existing novel fenofibrate formulations are forecasted to exceed $1 billion in annual U.S. sales.

"CIP-Fenofibrate is the first product from our pipeline to successfully receive FDA approval and we are actively pursuing opportunities to secure a U.S. commercial distribution agreement," said Larry Andrews, President of Cipher Pharmaceuticals. "CIP-Fenofibrate is one of three late-stage products in our pipeline. With an application for CIP-Isotretinoin under review with the FDA and preparations underway to file the CIP-Tramadol application with the FDA in the first half of 2006, we believe that the approval of CIP-Fenofibrate represents the first of a number of significant milestone events for Cipher."

CIP-Fenofibrate received approval for three unique fenofibrate dosages: 50, 100 and 150 mg, with the 150 mg strength equivalent to Tricor(R) 160 mg under fed conditions. With CIP-Fenofibrate, the extent of absorption is increased under high-fat conditions relative to low-fat conditions.

The approval provides for the use of CIP-Fenofibrate as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total-cholesterol (Total-C), triglycerides, apolipoprotein B (Apo B), and to increase high-density lipoprotein (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Frederickson Type IIa, IIb) in addition to the treatment of adult patients with hypertriglyceridemia (Frederickson Types IV and V hyperlipidemia).

Source: Cipher Pharmaceuticals Inc.

Recent Headlines

Scenesse is new treatment for people with rare, painful light sensitivity disease
Humira, Rituxan top list of drugs that added $5.1 billion to nation's health care bill
Lower court rulings cleared the way for generic versions of the MS drug
Maryland man wins lawsuit that alleges that the company's antipsychotic caused his gynecomastia
Antidepressants, ADHD meds are also used to self-poison
U.S. maintains measles elimination status as NY outbreak ebbs
Study lists steps that could save close to $300 billion a year
While many victims used THC, the cause remains elusive
Descovy joins Truvada, another Gilead product, in the HIV prophylaxis market